company background image
VNDA logo

Vanda Pharmaceuticals NasdaqGM:VNDA Stock Report

Last Price

US$4.41

Market Cap

US$257.1m

7D

0.2%

1Y

21.5%

Updated

02 Feb, 2025

Data

Company Financials +

Vanda Pharmaceuticals Inc.

NasdaqGM:VNDA Stock Report

Market Cap: US$257.1m

VNDA Stock Overview

A biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. More details

VNDA fundamental analysis
Snowflake Score
Valuation5/6
Future Growth4/6
Past Performance0/6
Financial Health6/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Vanda Pharmaceuticals Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Vanda Pharmaceuticals
Historical stock prices
Current Share PriceUS$4.41
52 Week HighUS$6.75
52 Week LowUS$3.46
Beta0.77
1 Month Change-9.07%
3 Month Change-9.07%
1 Year Change21.49%
3 Year Change-63.34%
5 Year Change-66.84%
Change since IPO-54.44%

Recent News & Updates

Vanda's Struggles Persist Despite New Drug Launches And Takeover Bids

Sep 05

Recent updates

Vanda's Struggles Persist Despite New Drug Launches And Takeover Bids

Sep 05

Vanda Pharmaceuticals: I Believe That The Bidding War Is Not Over

Aug 08

Vanda Pharmaceuticals: Undervalued With Promising Pipeline And Acquisition Interest

Jun 18

Vanda Pharmaceuticals: Fanapt Bipolar Win Doesn't Change Much

Apr 05

Vanda Pharmaceuticals' (NASDAQ:VNDA) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Feb 15
Vanda Pharmaceuticals' (NASDAQ:VNDA) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Vanda Pharmaceuticals' Portfolio Likely Has Upside From 2024 Approvals, Underpinned By Cash

Feb 13

Vanda Pharmaceuticals Inc.'s (NASDAQ:VNDA) Low P/S No Reason For Excitement

Feb 10
Vanda Pharmaceuticals Inc.'s (NASDAQ:VNDA) Low P/S No Reason For Excitement

News Flash: One Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Analyst Has Been Trimming Their Revenue Forecasts

Nov 11
News Flash: One Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Analyst Has Been Trimming Their Revenue Forecasts

One Forecaster Is Now More Bearish On Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Than They Used To Be

May 12
One Forecaster Is Now More Bearish On Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Than They Used To Be

Shareholder Returns

VNDAUS BiotechsUS Market
7D0.2%1.8%-0.8%
1Y21.5%-2.1%22.7%

Return vs Industry: VNDA exceeded the US Biotechs industry which returned -2.1% over the past year.

Return vs Market: VNDA underperformed the US Market which returned 22.7% over the past year.

Price Volatility

Is VNDA's price volatile compared to industry and market?
VNDA volatility
VNDA Average Weekly Movement5.1%
Biotechs Industry Average Movement11.2%
Market Average Movement6.4%
10% most volatile stocks in US Market18.7%
10% least volatile stocks in US Market3.2%

Stable Share Price: VNDA has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: VNDA's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2002203Mihael Polymeropouloswww.vandapharma.com

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson’s disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia.

Vanda Pharmaceuticals Inc. Fundamentals Summary

How do Vanda Pharmaceuticals's earnings and revenue compare to its market cap?
VNDA fundamental statistics
Market capUS$257.14m
Earnings (TTM)-US$16.39m
Revenue (TTM)US$190.86m

1.3x

P/S Ratio

-15.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
VNDA income statement (TTM)
RevenueUS$190.86m
Cost of RevenueUS$12.18m
Gross ProfitUS$178.67m
Other ExpensesUS$195.06m
Earnings-US$16.39m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.28
Gross Margin93.62%
Net Profit Margin-8.59%
Debt/Equity Ratio0%

How did VNDA perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/02 03:54
End of Day Share Price 2025/01/31 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Vanda Pharmaceuticals Inc. is covered by 20 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullArgus Research Company
Olivia BrayerBofA Global Research
Difei YangBrean Capital